Further, mutations within the IL2 promoter and IL2-receptor confer susceptibility to MS [50], [57], [58], and targeting the IL2 signaling pathway via IL2-receptor blocking antibodies is therapeutically beneficial in humans [59]. Here, IL2 is linked to myeloid sarcoma.